Submitted:
31 December 2024
Posted:
03 January 2025
You are already at the latest version
Abstract
Melanoma is an aggressive disease that arises from mutations in the cells that produce the pigment melanin, melanocytes. Melanoma is characterized by a high mortality rate, due to avoidance of applied therapies and metastasis to other organs [1]. The peculiar features of BNCT, particularly its cell-level selectivity of Boron Neutron Capture Therapy (BNCT), make BNCT a promising modality for melanoma treatment. However, appropriate cellular models should be used to study new therapies or improve the efficacy of existing therapies. Spheroids, which have been used for years for in vitro studies of the efficacy of anti-cancer therapies, have many characteristics shared with tumors by which they can increase the accuracy of the cellular response compared to 2D cultures in vitro studies, and in the future reduce the use of animals for research. To the best of our knowledge, when we started researching the use of spheroids in BNCT therapy in vitro, there was no publication showing such use. Our study aimed to evaluate the efficacy of a 3D cellular model (spheroids) for testing BNCT on melanoma cells. We assessed boronophenylalanine (10BPA) uptake using Inductively Coupled Plasma Mass Spectrometry in both spheroids and 2D cultures of melanoma and melanocytes. DNA damage, Ki67 protein expression, and spheroid growth were analyzed. The experimental groups included: (1) IR_B (neutron flux + 50 µg 10B/ml), (2) IR (neutron flux alone), (3) C_B (no irradiation, 50 µg 10B/ml), and (4) C (no irradiation and no treatment with boron). The total absorbed doses were estimated to 2.1 – 3.1 Gy for IR_B cells and spheroids as well as 8.3 – 9.4 Gy for IR_B spheroids, while estimated doses for IR cells were 0.5 – 1.9 Gy. Results indicated that IR_B spheroids had reduced diameters and significantly higher DNA damage compared to other groups. Melanoma cells in the 3D model showed higher DNA damage levels than those in the 2D model. Moreover, the Ki67 assay revealed differences in the expression of this marker between irradiated melanoma cell lines. In conclusion, preincubation with 10BPA enhances BNCT efficacy, leading to cell growth inhibition and increased DNA fragmentation. Differences in DNA damage between 2D and 3D models may be due to dissimilarities in cell metabolism caused by a changed cell architecture.

Keywords:
1. Introduction
2. Materials and Methods
2.1. Cell Cultures
2.2. BPA-Fructose Solution Preparation
2.3. Boron Uptake Experiments
2.4. Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Measurements
2.5. Neutron Irradiation. Experimental Design
2.6. DNA Damage Level – Comet Assay
2.7. Spheroids Growth Analysis
2.8. Proliferation Assay
2.9. Statistical Analysis Applied to the Obtained Data
3. Results
3.1. Boron Uptake Study
3.2. DNA Damage
3.3. Spheroids Growth Analysis
3.4. Proliferation Assay
4. Discussion
3.1. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A. Viability of Melanocytes and Melanoma Cells After Incubation with BPA
| Cell line | HEMa-LP | FM55p | WM266-4 |
|---|---|---|---|
| Time of incubation with BPA [h] | Viability [%] |
Viability [%] |
Viability [%] |
| 2 | 96.6 ± 0.3 | 97.6 ± 0.4 | 97.9 ± 0.3 |
| 4 | 95.7 ± 1.5 | 97.7 ± 0.2 | 97.6 ± 0.6 |
| 6 | 96.6 ± 0.4 | 97.3 ± 0.5 | 98.3 ± 0.4 |
| 12 | 97.1 ± 0.1 | 98.5 ± 0.1 | 98.6 ± 0.2 |
| Control | 98.2 ± 0.9 | 97.8 ± 0.7 | 98.8 ± 0.1 |
| Cell line | FM55p | WM266-4 |
|---|---|---|
| Time of incubation with BPA [h] | Viability [%] |
Viability [%] |
| 2 | 97.8 ± 1.2 | 99.8 ± 0.2 |
| 4 | 97.8 ± 2.2 | 99.8 ± 0.2 |
| 6 | 98.9 ± 0.2 | 99.8 ± 0.2 |
| 12 | 99.3 ± 0.7 | 98.8 ± 0.4 |
| Control | 99.7 ± 0.3 | 99.5 ± 0.1 |
Appendix B. Results of Student's t-test (p-Value) Comparing the Outcomes of the Comet Assay
- a)
- 2D cell cultures
| HEMa-LP cell line | Irradiated with neutrons after BPA incubation (IR_B) | Irradiated with neutrons (IR) |
| Time after irradiation | Control vs 2Gy | Control vs 2Gy |
| 1h | 0.0002 | 0.00697 |
| 24h | ns* | ns* |
| 1h: IR_B vs IR | <0.0001 | |
| 24h: IR_B vs IR | ns* | |
| * not significant. | ||
| FM55p cell line | Irradiated with neutrons after BPA incubation (IR_B) | Irradiated with neutrons (IR) |
| Time after radiation | Control vs 2Gy | Control vs 2Gy |
| 1h | <0.0001 | ns* |
| 24h | 0.0013 | ns* |
| 1h: IR_B vs IR | 0.0001 | |
| 24h: IR_B vs IR | 0.0073 | |
| * not significant. | ||
| WM266-4 cell line |
p-value IR_B |
p-value IR |
| Time after radiation | Control vs 2 Gy | Control vs 2 Gy |
| 1 h | ns* | ns* |
| 24 h | ns* | ns* |
| 1 h: IR_B vs IR | ns* | |
| 24 h: IR_B vs IR | ns* | |
| * not significant. | ||
- b)
- 3D cell cultures
| FM55p cell line | p-value IR_B | p-value IR | p-value | |||||
| Time after irradiation |
Control vs 2 Gy |
Control vs 6 Gy |
2 Gy vs 6 Gy |
Control vs 2 Gy |
Control vs 6 Gy |
2 Gy vs 6 Gy |
IR_B vs IR 2 Gy |
IR_B vs IR 6 Gy |
| 1 h | 0.011 | 0.001 | 0.001 | 0.001 | 0.006 | 0.010 | 0.001 | <0.0001 |
| 24 h | ns* | 0.002 | 0.038 | 0.008 | - | - | 0.028 | - |
| 48 h | ns* | ns* | ns* | ns* | - | - | 0.002 | - |
| * not significant. | ||||||||
| WM266-4 cell line | p-value IR_B | p-value IR | p-value | |||||
| Time after irradiation |
Control vs 2 Gy |
Control vs 6 Gy |
2 Gy vs 6 Gy |
Control vs 2 Gy |
Control vs 6 Gy |
2 Gy vs 6 Gy |
IR_B vs IR 2 Gy |
IR_B vs IR 6 Gy |
| 1 h | 0.003 | <0.0001 | 0.006 | ns* | ns* | ns* | 0.002 | <0.0001 |
| 24 h | ns* | 0.001 | 0.006 | ns* | ns* | 0.012 | ns* | ns* |
| 48 h | 0.032 | 0.002 | <0.0001 | 0.004 | ns* | 0.001 | 0.003 | 0.001 |
| * not significant. | ||||||||
Appendix C. Results of Student's t-Test (p-Value) Comparing the Outcomes of the Proliferation Assay – Ki67 Protein Level
- a)
- FM55p cell line spheroids
| p-value IR_B | p-value IR | p-value | ||||||
| Time after irradiation |
Control vs 2 Gy |
Control vs 6 Gy |
2 Gy vs 6 Gy |
Control vs 2 Gy |
Control vs 6 Gy |
2 Gy vs 6 Gy |
IR_B vs IR 2 Gy |
IR_B vs IR 6 Gy |
| 1 h | 0.03 | ns* | ns* | ns* | 0.04 | ns* | ns* | ns* |
| 24 h | ns* | ns* | ns* | ns* | - | - | ns* | - |
| 48 h | ns* | 0.04 | ns* | ns* | - | - | ns* | - |
| * not significant. | ||||||||
- b)
- WM266-4 cell line spheroids
| p-value IR_B | p-value IR | p-value | ||||||
| Time after irradiation |
Control vs 2 Gy |
Control vs 6 Gy |
2 Gy vs 6 Gy |
Control vs 2 Gy |
Control vs 6 Gy |
2 Gy vs 6 Gy |
IR_B vs IR 2 Gy |
IR_B vs IR 6 Gy |
| 1 h | ns* | 0.009 | ns* | ns* | ns* | ns* | ns* | ns* |
| 24 h | 0.005 | <0.0001 | 0.030 | ns* | 0.001 | ns* | ns* | <0.0001 |
| 48 h | 0.010 | 0.001 | 0.008 | 0.001 | ns* | 0.020 | ns* | 0.001 |
| * not significant. | ||||||||
References
- Dhanyamraju, P.K.; Patel, T.N., Melanoma therapeutics: a literature review. J. Biomed. Res. 2022, 36(2), 77-97. https://doi.org/10.7555/JBR.36.20210163. [CrossRef]
- Kanai, Y., Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Pharmacol. Ther. 2022, 230, 107964. https://doi.org/10.1016/j.pharmthera.2021.107964. [CrossRef]
- Zhang, Y.; Cai, J.; Hosmane, N.S.; Zhu, Y., In silico assessments of the small molecular boron agents to pave the way for artificial intelligence-based boron neutron capture therapy. Eur. J Med Chem. 2024, 279, 116841. https://doi.org/10.1016/j.ejmech.2024.116841. [CrossRef]
- Nedunchezhian, K.; Aswath, N.; Thiruppathy, M.; Thirugnanamurthy, S., Boron neutron capture therapy - a literature review. Journal of Clinical and Diagnostic Research 2016, 10(12), ZE01–4. https://doi.org/10.7860/JCDR/2016/19890.9024. [CrossRef]
- Silarski, M.; Dziedzic-Kocurek, K.; Szczepanek, M., Combined BNCT and PET for theranostics. Bio-Algorithms and Med-Systems 2021, 17(4), 293–300. https://doi.org/10.1515/bams-2021-0140. [CrossRef]
- Dymova, M.A.; Taskaev, S.Y.; Richter, V.A.; Kuligina ,E.V., Boron neutron capture therapy: Current status and future perspectives. Cancer Commun. 2020, 40(9), 406–21. https://doi.org/10.1002/cac2.12089. [CrossRef]
- Sauerwein, W.A.G.; Fischer, T.; Sancey, L.; Verry, C.; Matsuura, E.; Moss, R.L., et al. Principles, Recent Developments and Perspectives in Boron Neutron Capture Therapy (BNCT). Bio-Algorithms and Med-Systems 2023, 19(1), 48-53. https://doi.org/10.5604/01.3001.0054.1824. [CrossRef]
- Moss, R.L., Critical review, with an optimistic outlook, on Boron Neutron Capture Therapy (BNCT). Appl. Radiat. Isot. 2014, 88, 2-11. https://doi.org/10.1016/j.apradiso.2013.11.109. [CrossRef]
- Verlinden, B.; Van Hoecke, K.; Aerts, A.; Daems, N.; Dobney, A.; Janssens, K., et al. Quantification of boron in cells for evaluation of drug agents used in boron neutron capture therapy. J. Anal At Spectrom. 2021, 36(3), 598-606. https://doi.org/10.1039/D0JA00456A. [CrossRef]
- Karimi, H.; Leszczyński, B.; Kołodziej, T.; Kubicz, E.; Przybyło, M.; Stępień, E., X-ray microtomography as a new approach for imaging and analysis of tumor spheroids. Micron 2020, 137, 102917. https://doi.org/10.1016/j.micron.2020.102917. [CrossRef]
- Stępień, E.; Karimi, H.; Leszczyński, B.; Szczepanek, M., Melanoma spheroids as a model for cancer imaging study. Acta Phys. Polon. B 2020, 51, 159-163. https://doi.org/10.5506/APhysPolB.51.159. [CrossRef]
- Durak-Kozica, M.; Stępień, E.; Swakoń, J.; Moskal, P., Application of an ultra-high dose rate (FLASH) proton beam for the 3D cancer cell model – a proof of concept. Bio-Algorithms and Med-Systems 2023, 19(1), 31-4. https://doi.org/10.5604/01.3001.0054.1820. [CrossRef]
- El Harane, S.; Zidi, B.; El Harane, N.; Krause, K.H.; Matthes, T.; Preynat-Seauve, O., Cancer Spheroids and Organoids as Novel Tools for Research and Therapy: State of the Art and Challenges to Guide Precision Medicine. Cells 2023, 12(7), 1001. https://doi.org/10.3390/cells12071001. [CrossRef]
- Li, L.; Dai, K.; Li, J.; Shi, Y.; Zhang, Z.; Liu, T., et al. A Boron-10 nitride nanosheet for combinational boron neutron capture therapy and chemotherapy of tumor. Biomaterials 2021, 268, 120587. https://doi.org/10.1016/j.biomaterials.2020.120587. [CrossRef]
- Laird, M.; Matsumoto, K.; Higashi, Y.; Komatsu, A.; Raitano, A.; Morrison, K., et al. Organosilica nanoparticles containing sodium borocaptate (BSH) provide new prospects for boron neutron capture therapy (BNCT): efficient cellular uptake and enhanced BNCT efficacy. Nanoscale Adv. 2023, 5(9), 2537-2546. https://doi.org/10.1039/D2NA00839D. [CrossRef]
- Pinto, B.; Henriques, A.C.; Silva, P.M.A.; Bousbaa, H., Three-dimensional spheroids as in vitro preclinical models for cancer research. Pharmaceutics 2020, 12(12), 1-38. https://doi.org/10.3390/pharmaceutics12121186. [CrossRef]
- Nunes, A.S.; Barros, A.S.; Costa, E.C.; Moreira, A.F.; Correia, I.J., 3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs. Biotechnol Bioeng. 2019, 116(1), 206-226. https://doi.org/10.1002/bit.26845. [CrossRef]
- Costa, E.C.; Moreira, A.F.; de Melo-Diogo, D.; Gaspar, V.M.; Carvalho, M.P.; Correia, I.J., 3D tumor spheroids: an overview on the tools and techniques used for their analysis. Biotechnology Advances 2016, 34, 1427–1441. https://doi.org/10.1016/j.biotechadv.2016.11.002. [CrossRef]
- Gong, X.; Lin, C.; Cheng, J.; Su, J.; Zhao, H.; Liu, T., et al. Generation of multicellular tumor spheroids with microwell-based agarose scaffolds for drug testing. PLoS One 2015, 10(6), 1-18. https://doi.org/10.1371/journal.pone.0130348. [CrossRef]
- Carpano, M.; Perona, M.; Rodriguez, C.; Nievas, S.; Olivera, M.; Santa Cruz, G.A., et al. Experimental studies of boronophenylalanine (10BPA) biodistribution for the individual application of boron neutron capture therapy (BNCT) for malignant melanoma treatment. Int. J Radiat. Oncol. Biol. Phys 2015, 93(2), 344-52. https://doi.org/10.1016/j.ijrobp.2015.05.039. [CrossRef]
- Ferrari, M., Characterization of the gamma dose component in the BNCT irradiation facility and dosimetry for in vitro experiments at the Triga reactor in Pavia. Master thesis, University of Pavia, Pavia, Italy, 2013.
- Bortolussi, S.; Protti, N.; Ferrari, M.; Postuma, I.; Fatemi, S.; Prata, M., et al. Neutron flux and gamma dose measurement in the BNCT irradiation facility at the TRIGA reactor of the University of Pavia. Nucl. Instrum. Methods Phys. Res. B 2018, 414, 113-120. https://doi.org/10.1016/j.nimb.2017.10.023. [CrossRef]
- Sato, T.; Iwamoto, Y.; Hashimoto, S.; Ogawa, T.; Furuta, T.; Abe, S.I., et al. Recent improvements of the particle and heavy ion transport code system – PHITS version 3.33. J Nucl. Sci. Technol. 2024, 61(1), 127-135. https://doi.org/10.1080/00223131.2023.2275736. [CrossRef]
- Brown, F.B.; Kiedrowski, C.; Bull, J.S., MCNP5-1.60 Release Notes. Los Alamos National Laboratory Tech. Rep. LA-UR-10-06235, Los Alamos, NM, USA. 2010.
- Williams, R.G.; Gesh, I.C.J.; Pagh, R.T., Compendium of Material Composition Data for Radiation Transport Modeling. Available online: https://www.pnnl.gov/main/publications/external/technical_reports/pnnl-15870.pdf (accessed on 06 Oct 2024).
- ICRU Report 44, Tissue Substitutes in Radiation Dosimetry and Measurement – ICRU. Available online: https://www.icru.org/report/tissue-substitutes-in-radiation-dosimetry-and-measurement-report-44/ (accessed on 06 Oct 2024).
- Panek, A.; Miszczyk, J.; Swakoń, J., Biological effects and inter-individual variability in peripheral blood lymphocytes of healthy donors exposed to 60 MeV proton radiotherapeutic beam. Int. J. Radiat. Biol. 2018, 94(12), 1085–1094. https://doi.org/10.1080/09553002.2019.1524941. [CrossRef]
- Møller, P.; Azqueta, A.; Boutet-Robinet, E. et al., Minimum Information for Reporting on the Comet Assay (MIRCA): recommendations for describing comet assay procedures and results. Nat. Protoc. 2020, 15, 3817–3826. https://doi.org/10.1038/s41596-020-0398-1. [CrossRef]
- Karimi, H.; Moskal, P; Żak, A.; Stępień, E., 3D melanoma spheroid model for the development of positronium biomarkers. Sci. Rep. 2023 13, 7648. https://doi.org/10.1038/.
- Panek, D.; Szczepanek, M.; Leszczynski, B.; Moskal, P.; Stępień, E.Ł., Comparison of Lugol’s solution and Fe3O4 nanoparticles as contrast agents for tumor spheroid imaging using microcomputed tomography. Bio-Algorithms and Med-Systems 2022, 18(1), 158-162. https://doi.org/10.2478/bioal-2022-0084. [CrossRef]
- Wawrowicz, K.; Wierzbicki, M.; Stępień, E.Ł., Developing tumor microenvironment in rotating human melanoma cell cultures: study of novel preclinical model. Research Square 2024 preprint. https://doi.org/10.21203/rs.3.rs-4884972/v1. [CrossRef]
- Szczepanek, M., 3D melanoma model for in vitro BNCT studies : effects of neutron radiation on 10BPA-loaded melanoma spheroids. Doctoral thesis. Jagiellonian University, Kraków, Poland, 2024.
- Vörsmann, H.; Groeber, F.; Walles, H.; Busch, S.; Beissert, S.; Walczak, H., et al. Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. Cell Death & Disease 2013, 4(7), e719-e719. https://doi.org/10.1038/cddis.2013.249. [CrossRef]
- Monico, D.A.; Calori, I.R.; Souza, C.; Espreafico, E.M.; Bi, H.; Tedesco, A.C., Melanoma spheroid-containing artificial dermis as an alternative approach to in vivo models. Exp. Cell Res. 2022, 417, 113207. https://doi.org/10.1016/j.yexcr.2022.113207. [CrossRef]
- Dagrosa, A.; Carpano, M.; Perona, M.; Thomasz, L.; Nievas, S.; Cabrini, R., et al. Studies for the application of boron neutron capture therapy to the treatment of differentiated thyroid cancer. Appl. Radiat. Isot. 2011, 69(12), 1752-1755. https://doi.org/10.1016/j.apradiso.2011.02.030. [CrossRef]
- Dagrosa, M.A.; Pisarev, M.A.; Viaggi, M.; Kreimann, E.; Farías, S.; Garavaglia, R., et al. Selective uptake of p-borophenylalanine by undifferentiated thyroid carcinoma for boron neutron capture therapy. Thyroid 2002, 12(1), 7-12. https://doi.org/10.1089/105072502753451904. [CrossRef]
- Ferrari, C.; Zonta, C.; Cansolino, L.; Clerici, A.M.; Gaspari, A.; Altieri, S.; et al. Selective uptake of p-boronophenylalanine by osteosarcoma cells for boron neutron capture therapy. Appl. Radiat. Isot. 2009, 67, 2007–2010. https://doi.org/10.1016/j.apradiso.2009.03.059. [CrossRef]
- Sun, T.; Zhou, Y.; Xie, X.; Chen, G.; Li, B.; Wei, Y., et al. Selective uptake of boronophenylalanine by glioma stem/progenitor cells. Appl. Radiat. Isot. 2012, 70(8), 1512–1518. https://doi.org/10.1016/j.apradiso.2012.04.005. [CrossRef]
- Faião-Flores, F.; Coelho, P.R.P.; Arruda-Neto, J.D.T.; Camillo, M.A.P.; Maria-Engler, S.S.; Rici, R.E.G., et al. Boron uptake in normal melanocytes and melanoma cells and boron biodistribution study in mice bearing B16F10 melanoma for boron neutron capture therapy. Radiat. Environ. Biophys. 2012, 51(3), 319–329. https://doi.org/10.1007/s00411-012-0416-y. [CrossRef]
- Coderre, J.A.; Glass, J.D.; Packer, S.; Micca, P.; Greenberg, D., Experimental Boron Neutron Capture Therapy for Melanoma: Systematic Delivery of Boron to Melanotic and Amelanotic Melanoma. Pigment Cell Res. 1990, 3, 310-318. https://doi.org/10.1111/j.1600-0749.1990.tb00303.x. [CrossRef]
- Wittig, A.; Sauerwein, W.A.; Coderre, J.A.; Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. Radiat Res. 2000, 153(2), 173-180. https://doi.org/10.1667/0033-7587(2000)153[0173:motopb]2.0.co;2. [CrossRef]
- Szczepanek, M.; Panek, D.; Przybyło, M.; Moskal, P.; Stępień, E.Ł., Transcriptomic data analysis of melanocytes and melanoma cell lines of LAT transporter genes for precise medicine. Bio-Algorithms and Med-Systems 2022, 18(1), 144-150. https://doi.org/10.2478/bioal-2022-0086. [CrossRef]
- Yu, L.S.; Jhunjhunwala, M.; Hong, S.Y.; Yu, L.Y.; Lin, W.R.; Chen, C.S., Tissue architecture influences the biological effectiveness of boron neutron capture therapy in in vitro/in silico three-dimensional self-assembly cell models of pancreatic cancers. Cancers (Basel) 2021, 13(16), 4058. https://doi.org/10.3390/cancers13164058. [CrossRef]
- Rodriguez, C.; Carpano, M.; Curotto, P.; Thorp, S.; Casal, M.; Juvenal, G., et al. In vitro studies of DNA damage and repair mechanisms induced by BNCT in a poorly differentiated thyroid carcinoma cell line. Radiat Environ. Biophys 2018, 57(2), 143-152. https://doi.org/10.1007/s00411-017-0729-y. [CrossRef]
- Chen, K.H.; Lai, Z.Y.; Li, D.Y.; Lin, Y.C.; Chou, F.I.; Chuang, Y.J., Analysis of DNA damage responses after boric acid-mediated boron neutron capture therapy in hepatocellular carcinoma. Anticancer Res. 2019, 39(12), 6661-6671. https://doi.org/10.21873/anticanres.13881. [CrossRef]
- Faião-Flores, F.; Coelho, P.R.P.; Toledo Arruda-Neto, J.D.; Maria-Engler, S.S.; Tiago, M.; Capelozzi, V.L., et al. Apoptosis through Bcl-2/Bax and Cleaved Caspase Up-Regulation in Melanoma Treated by Boron Neutron Capture Therapy. PLoS One 2013, 8(3), 1-12. https://doi.org/10.1371/journal.pone.0059639. [CrossRef]
- Yu, L.Y.; Hsu, C.H.; Li, C.Y.; Hong, S.Y.; Chen, C.R.; Chen, C.S., Evaluating the biological effectiveness of boron neutron capture therapy by using microfluidics-based pancreatic tumor spheroids. Analyst 2023, 148(13), 3045–3056. https://doi.org/10.1039/D2AN01812H. [CrossRef]
- Sun, T.; Zhang, Z.; Li, B.; Chen, G.; Xie, X.; Wei, Y., et al. Boron neutron capture therapy induces cell cycle arrest and cell apoptosis of glioma stem/progenitor cells in vitro. Radiation Oncology 2013 8(1), 1-8. https://doi.org/10.1186/1748-717X-8-195. [CrossRef]
- Perona, M.; Pontiggia, O.; Carpano, M.; Thomasz, L.; Thorp, S.; Pozzi, E., et al. In vitro studies of cellular response to DNA damage induced by boron neutron capture therapy. Appl. Radiat. Isot. 2011, 69(12), 1732–1736. https://doi.org/10.1016/j.apradiso.2011.03.044. [CrossRef]







| Parameter | Value |
|---|---|
| RF power [W] | 1250 |
| Vacuum pressure [bar] | 9.86⋅10-9 |
| Nebulizing gas flow ml/min] | 1.04 |
| Cooling gas flow [ml/min] | 17.00 |
| Auxiliary gas flow [ml/min] | 1.02 |
| Lens voltage [V] | 10 |
| Cell line | Reactor power [kW] | Φt [cm-2s-1] |
CB [ppm] |
Dtot [Gy] |
D0 [Gy] |
|---|---|---|---|---|---|
| WM266-4 2D | 20 | 9.60 ⋅ 108 | 27.5 ± 0.5 | 2.05 ± 0.05stat ± 0.14sys | 0.33 ± 0.01stat ± 0.04sys |
| FM55p 2D | 60 | 2.88 ⋅ 109 | 9.2 ± 2.0 | 2.71 ± 0.38stat ± 0.40sys | 0.98 ± 0.02stat ± 0.04sys |
| HEMa-LP | 20 | 9.60 ⋅ 108 | 26.4 ± 1.7 | 1.98 ± 0.12stat ± 0.14sys | 0.33 ± 0.01stat ± 0.04sys |
| WM266-4 3D | 17 | 8.16 ⋅ 108 | 36.0 ± 6.8 | 3.14 ± 0.48stat ± 0.07sys | 0.61 ± 0.03stat ± 0.07sys |
| FM55p 3D | 12 | 5.76 ⋅ 108 | 47.5 ± 4.6 | 2.78 ± 0.24stat ± 0.05sys | 0.43 ± 0.02stat ± 0.03sys |
| WM266-4 3D | 51 | 2.45 ⋅ 109 | 36.0 ± 6.8 | 9.33 ± 1.50stat ± 0.2sys | 1.82 ± 0.09stat ± 0.20sys |
| FM55p 3D | 36 | 1.73 ⋅ 109 | 47.5 ± 4.6 | 8.30 ± 0.80stat ± 0.14sys | 1.28 ± 0.07stat ± 0.14sys |
| Cell culture | [mGy/s] | [mGy/s] | [mGy/s] | [mGy/s] | [mGy/s] |
|---|---|---|---|---|---|
| 2D | 9.79 ± 0.09 | 1.31 ± 0.01 | 0.699 ± 0.001 | 3.28 ± 0.01 | 5.81 ± 0.07 |
| Spheroids | 14.98 ± 0.08 | 1.70 ± 0.03 | 0.119 ± 0.005 | 4.26 ± 0.08 | 10.6 ± 0.7 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).